EOLS Stock Down -37% after 6-Day Loss Streak
Evolus (EOLS) stock hit day 6 of a continuous streak of days with losses, with cumulative losses over this period amounting to a -37% return. The company has lost about $138 Mil in value over the last 6 days, with its current market capitalization at about $372 Mil. The stock remains 47.7% below its value at the end of 2024. This compares with year-to-date returns of 8.4% for the S&P 500.
EOLS provides medical aesthetic products, including a proprietary botulinum toxin formulation for treating moderate to severe glabellar lines in adults, serving physicians and patients in the U.S. Is this drop a warning sign or a setup for rebound? Deep dive with Buy or Sell EOLS.
Comparing EOLS Stock Returns With The S&P 500
The following table summarizes the return for EOLS stock vs. the S&P 500 index over different periods, including the current streak:
- Why Is Merck Stock Still Undervalued After An 80% Surge?
- Figure’s Take Rate Is Shrinking By Design
- Make Your TDG Shares Pay You 9.8% A Year While You Hold Them
- The Options Market Puts PayPal Stock Between The High Forties And The High Seventies
- What Could Power The Next Rally In McDonald’s Stock
- What You Are Really Paying For In Arista Networks Stock
| Return Period | EOLS | S&P 500 |
|---|---|---|
| 1D | -2.2% | -0.3% |
| 6D (Current Streak) | -36.9% | 2.2% |
| 1M (21D) | -39.1% | 1.8% |
| 3M (63D) | -41.1% | 12.6% |
| YTD 2025 | -47.7% | 8.4% |
| 2024 | 4.8% | 23.3% |
| 2023 | 40.2% | 24.2% |
| 2022 | 15.4% | -19.4% |
What is the point? Sustained weakness can be more than noise. It often signals shifting sentiment or deeper concerns. A multi-day losing streak may warn of further downside, or present an opportunity to buy if fundamentals are intact. Take a look at what history tells you about whether past dips like this have been buying opportunities or traps: EOLS Dip Buyer Analysis.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 49 S&P constituents with 3 days or more of consecutive gains and 62 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 27 | 37 |
| 4D | 11 | 14 |
| 5D | 1 | 9 |
| 6D | 8 | 0 |
| 7D or more | 2 | 2 |
| Total >=3 D | 49 | 62 |
Key Financials for Evolus (EOLS)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $202.1 Mil | $266.3 Mil |
| Operating Income | $-45.0 Mil | $-27.2 Mil |
| Net Income | $-61.7 Mil | $-50.4 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ1 | 2025 FQ2 |
|---|---|---|
| Revenues | $68.5 Mil | $69.4 Mil |
| Operating Income | $-13.0 Mil | $-14.1 Mil |
| Net Income | $-18.9 Mil | $-17.1 Mil |
The losing streak EOLS stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.